Compositions and methods for preventing retention of psma-targeted therapy
OwnerZhenghong Lee, James Basilion +2inventors
InventorsZhenghong Lee, James Basilion, William Julian, Olga Sergeeva
Life of this patent
Estimating the term…
Abstract
A method of inhibiting accumulation and/or retention of a prostate-specific membrane antigen (PSMA)-targeted therapy to a non-cancer tissue in a subject includes administering to a subject being treated with the PSMA-targeted therapy a pharmacologically effective amount of an agent that inhibits PSMA-mediated cellular retention of the PSMA-targeted therapy by the non-cancer tissue.
Claims24
A method of inhibiting accumulation and/or retention of a prostate-specific membrane antigen (PSMA)-targeted therapy in PSMA expressing non-cancer tissue of a subject, the method comprising:
- administering to a subject being treated with the PSMA-targeted therapy a pharmacologically effective amount of an agent that inhibits PSMA-mediated cellular retention of the PSMA-targeted therapy by the non-cancer tissue, wherein the agent comprises an inhibitor of clathrin mediated endocytosis, an aquaporin (AQP) inhibitor, or an aquaglyceroporin inhibitor.
(canceled)
(canceled)
A method of reducing PSMA-targeted radioligand therapy induced salivary gland and/or lacrimal gland damage in a subject receiving PSMA-targeted radioligand therapy for cancer, the method comprising:
- administering to the subject a pharmacologically effective amount of an agent that inhibits PSMA-mediated cellular uptake and/or retention of the PSMA-targeted radioligand therapy by the non-cancer salivary gland tissues and/or lacrimal gland tissues in the subject, wherein the agent comprises an inhibitor of clathrin mediated endocytosis, an aquaporin (AQP) inhibitor, or an aquaglyceroporin inhibitor.
22-37. (canceled)
A method of treating PSMA expressing cancer in a subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of PSMA-targeted radioligand and a therapeutically effective amount of an agent that inhibits PSMA-mediated cellular retention of the PSMA-targeted radioligand by non-cancer salivary gland tissues and/or lacrimal gland tissues in the subject, wherein the agent comprises an inhibitor of clathrin mediated endocytosis, an aquaporin (AQP) inhibitor, or an aquaglyceroporin inhibitor.
39-76. (canceled)
Dependencies are inferred from the claim text.